March 30, 2012
Amyloid Beta In The Brain Of Individuals With Alzheimer’s Disease
The deposition of amyloid beta in the brain of individuals with Alzheimer's disease is the focus of much research into both its cause and treatment.
While there may not be a consensus as to whether the deposition contributes to the disease or is a consequence of the disease, there is agreement that it is not favored thermodynamically, meaning that something else is promoting the process.
Professor Exley said: "We have shown that SAP is bound by fibrils of amyloid beta and that this interaction stabilizes the fibrils over timescales which are physiologically significant. This is the first example of a physiologically significant biomolecule promoting and stabilizing the formation of amyloid fibrils of amyloid beta 42 under near-physiological conditions."
The group also found that this property of SAP was enhanced in the presence of aluminum, a metal which has also been shown to be co-deposited with amyloid beta in Alzheimer's disease. There have been recent efforts to reduce the plasma concentration of SAP as a therapy for Alzheimer's disease and the research provides strong evidence that SAP is involved in the deposition of amyloid beta 42 in Alzheimer's disease and that by reducing the plasma concentration of SAP it might also reduce the deposition of amyloid beta. Their observations support serum amyloid P component as a therapeutic target in Alzheimer's disease.
On the Net: